{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:40:58Z","timestamp":1787024458326,"version":"build-2736575974"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["VHRM"],"DOI":"10.2147\/vhrm.s10952","type":"journal-article","created":{"date-parts":[[2010,9,10]],"date-time":"2010-09-10T00:39:47Z","timestamp":1284079187000},"page":"541","source":"Crossref","is-referenced-by-count":96,"title":["Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience"],"prefix":"10.2147","author":[{"family":"Foley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2010,7]]},"container-title":["Vascular Health and Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=6689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T18:04:45Z","timestamp":1477850685000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/weight-neutrality-with-the-dpp-4-inhibitor-vildagliptin-mechanistic-ba-peer-reviewed-article-VHRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/vhrm.s10952","relation":{},"ISSN":["1178-2048"],"issn-type":[{"value":"1178-2048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}